Sanofi: agreement with Canada on Covid-19 vaccine
(CercleFinance.com) - Sanofi and GSK announce that they have signed agreements with the government of Canada to supply up to 72 million doses of their adjuvanted Covid-19 vaccine, starting in 2021.
Both companies operate vaccine manufacturing facilities in Canada that are contributing to the development of a vaccine against Covid-19.
Sanofi and GSK launched a Phase I/II trial on 3 September, for which 440 participants are being recruited.
Both companies expect to obtain the first results in early December 2020 and to be in a position to launch a pivotal Phase III trial before the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Both companies operate vaccine manufacturing facilities in Canada that are contributing to the development of a vaccine against Covid-19.
Sanofi and GSK launched a Phase I/II trial on 3 September, for which 440 participants are being recruited.
Both companies expect to obtain the first results in early December 2020 and to be in a position to launch a pivotal Phase III trial before the end of the year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.